PMID- 26031576
OWN - NLM
STAT- MEDLINE
DCOM- 20151113
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 64
IP  - 9
DP  - 2015 Sep
TI  - Genetic susceptibility to cervical squamous cell carcinoma is associated with 
      HLA-DPB1 polymorphisms in Taiwanese women.
PG  - 1151-7
LID - 10.1007/s00262-015-1721-5 [doi]
AB  - Cervical cancer is a multifactorial disease, and increasing evidence suggests 
      that host immunogenetic background may contribute to its pathogenesis. Genetic 
      variations in human leukocyte antigen (HLA) genes may alter the efficiency of 
      immune response to human papillomavirus (HPV) antigens and have been implicated 
      in the risk of cervical cancer. We investigated whether polymorphisms in the 
      HLA-DPB1 gene were associated with cervical cancer risk in a Taiwanese 
      population. HLA-DPB1 alleles and +550 G/A polymorphism were genotyped in a 
      case-control study of 473 women with cervical squamous cell carcinoma (CSCC) and 
      676 healthy controls. The presence and genotypes of HPV in CSCC were determined. 
      We found that the DPB1*05:01 and +550 A alleles were associated with decreased 
      and increased risk of CSCC, respectively [odds ratio (OR) = 0.72, Pc = 0.001; OR 
      = 1.25, Pc = 0.03]. In subgroup analysis based on HPV type 16 positivity, 
      significant associations were shown in the DPB1*05:01 and *13:01 alleles (OR = 
      0.65, Pc = 0.0007; OR = 1.83, Pc = 0.004). Furthermore, the DPB1*05:01-G and 
      *13:01-G haplotypes conferred decreased and increased risk of both CSCC and 
      HPV-16 positive CSCC women, respectively (OR = 0.72, Pc = 0.0009; OR = 0.63, Pc = 
      0.0004 for DPB1*05:01-G; OR = 1.55, Pc = 0.03; OR = 1.84, Pc = 0.004 for 
      DPB1*13:01-G). A risk haplotype DPB1*02:01-A was also observed in the HPV-16 
      positive CSCC women (OR = 1.51, Pc = 0.05). These findings suggest that HLA-DPB1 
      gene is involved in the CSCC development.
FAU - Yang, Yuh-Cheng
AU  - Yang YC
AD  - Department of Gynecology and Obstetrics, Mackay Memorial Hospital, Taipei City, 
      Taiwan.
FAU - Chang, Tzu-Yang
AU  - Chang TY
FAU - Chen, Tze-Chien
AU  - Chen TC
FAU - Lin, Wen-Shan
AU  - Lin WS
FAU - Chang, Shih-Chuan
AU  - Chang SC
FAU - Lee, Yann-Jinn
AU  - Lee YJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150602
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (HLA-DP beta-Chains)
RN  - 0 (HLA-DPB1 antigen)
SB  - IM
MH  - Carcinoma, Squamous Cell/epidemiology/*genetics/immunology
MH  - Case-Control Studies
MH  - Female
MH  - Genetic Predisposition to Disease
MH  - HLA-DP beta-Chains/*genetics/immunology
MH  - Humans
MH  - Middle Aged
MH  - Polymorphism, Genetic
MH  - Taiwan/epidemiology
MH  - Uterine Cervical Neoplasms/epidemiology/*genetics/immunology
PMC - PMC11028884
COIS- The authors declare that they have no conflict of interest.
EDAT- 2015/06/03 06:00
MHDA- 2015/11/14 06:00
PMCR- 2015/06/02
CRDT- 2015/06/03 06:00
PHST- 2014/11/26 00:00 [received]
PHST- 2015/05/21 00:00 [accepted]
PHST- 2015/06/03 06:00 [entrez]
PHST- 2015/06/03 06:00 [pubmed]
PHST- 2015/11/14 06:00 [medline]
PHST- 2015/06/02 00:00 [pmc-release]
AID - 1721 [pii]
AID - 10.1007/s00262-015-1721-5 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2015 Sep;64(9):1151-7. doi: 10.1007/s00262-015-1721-5. 
      Epub 2015 Jun 2.